Adicet stockholders approve 2018 equity plan increase, elect directors at annual meeting

Proposal 1 - Election of Class II Director Nominees The stockholders of the Company elected Carl L. Gordon, Ph.D., Steve Dubin, and Jeffrey Chodakewitz, M.D. as Class II directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2026 and until their successors have been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class II directors were as follows: Name Votes For Votes Withheld Broker Non-Votes Carl L. Gordon, Ph.D. 23,974,856 8,264,214 3,636,755 Steve Dubin 25,969,684 6,269,386 3,636,755 Jeffrey Chodakewitz, M.D. 30,419,543 1,819,527 3,636,755

Proposal 3 – Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such ratification were as follows: Votes For Votes Against Abstain 35,860,385 12,396 3,044

Proposal 2 – Approval of Adicet Bio, Inc. Second Amended and Restated 2018 Stock Option and Incentive Plan The stockholders of the Company approved the 2018 Plan. The results of the stockholders’ vote with respect to the approval of the 2018 Plan were as follows: Votes For Votes Against Abstain Broker Non-Votes 20,110,285 12,126,179 2,606 3,636,755